Minimal Residual Disease Assessment hos patienter med kolorektal cancer, MiRDA-C-undersøgelsen
Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)
This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.
Studieoversigt
Status
Status
Betingelser
Betingelser
- Kolorektalt adenokarcinom
- Stage IVA tyktarmskræft AJCC v8
- Stadie IVB tyktarmskræft AJCC v8
- Stadie IVC tyktarmskræft AJCC v8
- Fase III kolorektal cancer AJCC v8
- Fase IIIA tyktarmskræft AJCC v8
- Fase IIIB tyktarmskræft AJCC v8
- Fase IIIC tyktarmskræft AJCC v8
- Fase I tyktarmskræft AJCC v8
- Fase II kolorektal cancer AJCC v8
- Fase IIA kolorektal cancer AJCC v8
- Fase IIB tyktarmskræft AJCC v8
- Fase IIC kolorektal cancer AJCC v8
- Fase IV kolorektal cancer AJCC v6
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. Demonstrate ability to monitor cancer-specific deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and proteomic alterations from plasma.
II. Improve detection of recurrences post completion of curative therapies through monitoring of plasma cancer-specific DNA, RNA and proteomic alterations.
SECONDARY OBJECTIVES:
I. Qualitative and quantitative changes in cancer-specific plasma alterations during neoadjuvant, adjuvant therapies and surveillance.
II. Disease free survival (DFS) of patients with detectable cancer-specific plasma alterations.
III. Overall survival (OS) of patients with detectable cancer-specific plasma alterations.
EXPLORATORY OBJECTIVES:
I. Optimal combination of cancer-specific plasma DNA, RNA and / or proteomic alterations for early detection of recurrences.
II. Sensitivity, specificity, positive predictive and negative predictive values of cancer-specific plasma alterations in detecting recurrences.
III. Correlation between cancer-specific alterations in plasma and tissue and either with outcomes including DFS & OS.
IV. Nature and frequency of detection of incidental non-colorectal cancer related DNA, RNA and / or proteomic alterations.
OUTLINE:
Patients undergo collection of blood samples at baseline, during each neoadjuvant therapy treatment, prior to surgical resection, and up to 4 times per year for up to 5 years. Patients also undergo collection of tissue sample at time of surgical resection. Patients' medical records may also be reviewed.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Arvind Dasari
- Telefonnummer: (713) 792-2828
- E-mail: adasari@mdanderson.org
Studiesteder
-
-
Arizona
-
Gilbert, Arizona, Forenede Stater, 85234
- Afsluttet
- Banner - MD Anderson Cancer Center
-
-
Florida
-
Jacksonville, Florida, Forenede Stater, 32207
- Afsluttet
- Baptist- MD Anderson Cancer Center
-
-
Hawaii
-
Honolulu, Hawaii, Forenede Stater, 96813
- Afsluttet
- The Queen's Medical Center
-
-
Idaho
-
Boise, Idaho, Forenede Stater, 83712
- Afsluttet
- St. Luke's Cancer Institute
-
-
New Jersey
-
Camden, New Jersey, Forenede Stater, 08103
- Afsluttet
- Cooper Hospital UNIV MED CTR.
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75390
- Afsluttet
- UT Southwestern/Simmons Cancer Center-Dallas
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- M D Anderson Cancer Center
-
Kontakt:
- Arvind Dasari
- Telefonnummer: 713-792-2828
- E-mail: adasari@mdanderson.org
-
Ledende efterforsker:
- Arvind Dasari
-
Houston, Texas, Forenede Stater, 77030
- Afsluttet
- Houston Methodist Cancer Center
-
San Antonio, Texas, Forenede Stater, 78229
- Afsluttet
- UT Health San Antonio MD Anderson Cancer Center
-
Temple, Texas, Forenede Stater, 76508
- Afsluttet
- Baylor Scott & White Research Institute
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients with colorectal cancer at MD Anderson Cancer Center.
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years.
- Histological/cytological confirmation of colorectal adenocarcinoma.
- Patients with any stage colorectal adenocarcinoma deemed potentially eligible for curative intent treatment. Patients with stages II-IV colorectal cancer post-R0 resection may also be enrolled onto the protocol any time before or up to 3 months post-surgery and prior to initiating adjuvant therapy.
- Ability to understand and the willingness to sign a written informed consent document.
- Willing to pursue standard of care surveillance post completion of curative therapies.
- Willing to provide blood samples for correlative research.
Exclusion Criteria:
- Known active malignancies other than colorectal adenocarcinoma that may interfere with detection and / or interpretation of circulating plasma markers. Patients with known clonal hematopoiesis of indeterminate potential are eligible.
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Ancillary-correlative (biospecimen collection)
Patients undergo collection of blood samples at baseline, during each neoadjuvant therapy treatment, prior to surgical resection, and up to 4 times per year for up to 5 years. Patients also undergo collection of tissue sample at time of surgical resection. Patients medical records may also be reviewed. |
Review of medical records Undergo collection of blood and tissue samples |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Analysis of deoxyribonucleic (DNA), ribonucleic acid (RNA), and proteomic alterations from plasma
Tidsramme: Up to 5 years
|
To detect circulating tumor DNA (ctDNA) in plasma samples from patients with colorectal cancer (CRC) who have completed curative therapies (i.e. minimal residual disease) towards predicting recurrence earlier than the current standard of care utilizing the CRC23 assay and the LUNAR assay from Guardant Health technology. |
Up to 5 years
|
|
Detection of recurrences post completion of curative therapies
Tidsramme: Up to 5 years
|
To detect ctDNA in plasma samples from patients with CRC who have completed curative therapies (i.e. minimal residual disease) towards predicting recurrence earlier than the current standard of care utilizing the CRC23 assay and the LUNAR assay from Guardant Health technology. |
Up to 5 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Sygdomsfri overlevelse (DFS)
Tidsramme: Op til 5 år
|
Op til 5 år
|
|
|
Samlet overlevelse (OS)
Tidsramme: Op til 5 år
|
Op til 5 år
|
|
|
Changes in cancer-specific plasma alterations during neoadjuvant, adjuvant therapies and surveillance
Tidsramme: Baseline up to 5 years
|
Will assess the association between changes in circulating molecules and response in patients undergoing neoadjuvant therapy by linear or logistic regression models |
Baseline up to 5 years
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Optimal kombination af cancerspecifikt plasma-DNA, RNA og/eller proteomiske ændringer til tidlig påvisning af recidiv
Tidsramme: Op til 5 år
|
Op til 5 år
|
|
Sensitivitet, specificitet, positive prædiktive og negative prædiktive værdier af cancerspecifikke plasmaændringer ved påvisning af tilbagefald
Tidsramme: Op til 5 år
|
Op til 5 år
|
|
Korrelation mellem kræftspecifikke ændringer i plasma og væv og enten med resultater inklusive DFS & OS
Tidsramme: Op til 5 år
|
Op til 5 år
|
|
Arten og hyppigheden af påvisning af tilfældige ikke-kolorektal cancerrelateret DNA, RNA og/eller proteomiske ændringer
Tidsramme: Op til 5 år
|
Op til 5 år
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Arvind Dasari, M.D. Anderson Cancer Center
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- PA18-1171
- PA18-1171 (Anden identifikator: M D Anderson Cancer Center)
- NCI-2020-10034 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .